FindTrial
Sign In

Comparative study to assess effectiveness and Safety of Amlodipine and Telmisartan.

Effectiveness and Safety of Amlodipine and Telmisartan in Treatment Naïve Hypertension: An EMR-based Retrospective, Comparative Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/02/062389
Enrollment
2000
Registered
2024-02-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Control Intervention1: Nil: Nil

Sponsors

Dr Reddys Laboratories Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Treatment-naïve patients with essential or primary hypertension. Patients who were prescribed amlodipine or telmisartan monotherapy as first line therapy.

Exclusion criteria

Exclusion criteria: Patients with secondary hypertension. Patients prescribed with any other antihypertensive drug Patients prescribed with any combination of antihypertensive drugs

Design outcomes

Primary

MeasureTime frame
Change in SBP and DBP from baseline to 12 weeks.Timepoint: An interim visit of 2 weeks and a final visit of 12 weeks will be considered for analysis.—

Secondary

MeasureTime frame
Change in heart rate and assessment of pedal edemaTimepoint: Baseline to 2, and 12 weeks.—

Countries

India

Contacts

Public ContactDr Sagar Katare

Dr Reddys Laboratories Limited

mujtabanaqvi@drreddys.com7032969523

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026